Skip to main content

Table 4 Statistical analysis of three groups of POLAR validation set for 0–10 years of follow-up

From: Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer

  All POLAR patients Chemotherapy-treated Chemotherapy-naive
0–10 Years
No. of patients (relapses) n = 422 (247) n = 170 (99) n = 252 (148)
Univariate CTS LRχ2 11.23 7.75 6.1
P < 0.001 0.005 0.014
C-index (SE) 0.594 (0.028) 0.623 (0.044) 0.590 (0.036)
10-Year signature LRχ2 12.44 7.73 5.39
P < 0.004 0.005 0.020
C-index (SE) 0.593 (0.028) 0.619 (0.044) 0.578 (0.037)
Multivariable comparisons CTS + 10-year signature vs CTS ΔLRχ2 7.74 6.71 2.47
P 0.005 0.001 0.116
CTS + 10-year signature C-index (SE) 0.617 (0.028) 0.669 (0.042) 0.598 (0.036)
  1. Abbreviations: POLAR Molecular Predictors Of early versus LAte Recurrence in ER-positive breast cancer, CTS Clinical Treatment Score, LR Likelihood ratio, SE standard error
  2. Both univariate and multivariable analyses are presented for years 0–10, years 0–5, and years 5–10 separately. Likelihood ratio test based on Cox proportional hazards models for univariate and multivariable analyses. Differences in likelihood ratio values (ΔLRχ2) were used. CTS was used as a covariate in the multivariable regressions